title: The FDA, Juno Therapeutics, and the ethical imperative of transparency.
authors.affiliation: Program on Regulation, Therapeutics, and Law (PORTAL), division of pharmacoepidemiology and pharmacoeconomics, Brigham and Women's Hospital, Boston, US Harvard Center for Bioethics, Harvard Medical School, Boston, US.
authors.forename: Spencer Phillips
authors.initials: SP
authors.lastname: Hey
authors.affiliation: Program on Regulation, Therapeutics, and Law (PORTAL), division of pharmacoepidemiology and pharmacoeconomics, Brigham and Women's Hospital, Boston, US Harvard Center for Bioethics, Harvard Medical School, Boston, US.
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Kesselheim
mesh_terms: D001929:Brain Edema / Q000139:chemically induced*; D017322:Clinical Trials, Phase II as Topic / Q000941:ethics*; D030881:Disclosure / Q000941:ethics*; D004345:Drug Industry / Q000941:ethics*; D015507:Drugs, Investigational / Q000009:adverse effects*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects* / Q000941:ethics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D056737:Safety-Based Drug Withdrawals / Q000941:ethics*; D014481:United States; D014486:United States Food and Drug Administration / Q000941:ethics*; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D015507:Drugs, Investigational; D014740:Vidarabine; C024352:fludarabine